BG
PGNX

BlackRock Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

BlackRock Group’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$243K Buy
28,025
+2,751
+11% +$20.3K ﹤0.01% 2609
2016
Q3 		$161K Buy
25,274
+1,179
+5% +$7.13K ﹤0.01% 2696
2016
Q2 		$102K Sell
24,095
-394
-2% -$1.9K ﹤0.01% 2788
2016
Q1 		$106K Buy
24,489
+9,039
+59% +$40.3K ﹤0.01% 2750
2015
Q4 		$95K Sell
15,450
-525
-3% -$3.44K ﹤0.01% 2697
2015
Q3 		$91K Buy
15,975
+3,808
+31% +$29.2K ﹤0.01% 2727
2015
Q2 		$91K Buy
+12,167
New +$73.6K ﹤0.01% 2775

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's PGNX Position: Q4 2016 in Review

BlackRock Group increased its Progenics Pharmaceuticals Inc (PGNX) stake by 11% in Q4 2016, buying an estimated $20.3K and bringing the position to 28,025 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #2609.

BlackRock Group first reported a position in PGNX in Q2 2015 and has held it in 7 quarters since. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • BlackRock Group held 28,025 shares of Progenics Pharmaceuticals Inc worth $243K as of Q4 2016.
  • BlackRock Group bought 2,751 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $20.3K.
  • Progenics Pharmaceuticals Inc made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2609 holding.
  • BlackRock Group first reported a position in Progenics Pharmaceuticals Inc in Q2 2015 and has held it in 7 quarters since.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.